Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meetings, 42687 [2017-19089]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 174 / Monday, September 11, 2017 / Notices
HIV-positive adults. VRC01 is currently
being evaluated in a phase II clinical
trial for prevention of HIV–1
acquisition.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Monoclonal antibodies to treat and/or
diagnose HIV and/or AIDS
• Immunoassays and kits
Competitive Advantages
• Monoclonal neutralizing antibodies
prevent viral entry into cells
• Monoclonal neutralizing antibodies
can be used for vaccine design and to
develop diagnostics for HIV–1
Development Stage
•
•
•
•
In vitro data available
In vivo data available (animal)
In vivo data available (human)
Clinical Phase I
Inventors: John Mascola, Mark
Connors, Peter Kwong, Gary Nabel,
Mario Roederer, Xueling Wu (all from
NIAID).
Publications
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Nabel G et al. (2015) Broadly
Neutralizing Human
Immunodeficiency Virus Type 1
Antibody Gene Transfer Protects
Nonhuman Primates from Mucosal
Simian-Human Immunodeficiency
Virus Infection. J Virol.
89(16):8334–45. [PMID26041300].
Nabel G et al. (2014) Enhanced potency
of a broadly neutralizing HIV–1
antibody in vitro improves
protection against lentiviral
infection in vivo. J Virol.
88(21):12669–82. [PMID:25142607].
Wu X et al. (2010) Immunotypes of a
quaternary site of HIV–1
vulnerability and their recognition
by antibodies. J Virol. 2011:
85(9):4578–85. [PMID:21325411].
Zhou T et al. (2010) Structural basis for
broad and potent neutralization of
HIV–1 by antibody VRC01. Science.
329(5993):811–7. [PMID:
20616231].
Intellectual Property: HHS Reference
No: E–300–2009 and E–051–2012. The
E–300–2009 family includes U.S. Patent
Application. 13/498,286, filed March
23, 2012 (Issued); Australia Patent
Application 2010298025, filed
September 24, 2010 (Issued); China
Patent Application 201080053616.5
filed September 24, 2010 (Issued); E.U.
Patent Application 10760878.8 filed
VerDate Sep<11>2014
16:34 Sep 08, 2017
Jkt 241001
September 24, 2010 (Pending); India
Patent Application 588/KOLNP/2012
filed March 13, 2012 (Pending); South
Africa Patent Application 212/02116
filed September 24, 2017 (Pending);
Canada Patent Application. 2274636
filed September 24, 2017 (Pending).
The E–051–2012 family includes U.S.
Patent Application 14–363,740, filed
June 6, 2014 (Issued); Australia Patent
Application. 2012347453, filed
December 10,2010 (Issued); China
Patent Application 201280069415.3,
filed December 10, 2012 (Pending); E.U.
Patent Application 1285597.6, filed
December 10, 2012 (Pending); Indian
Patent Application 4661/DELNP/2014,
filed December 10, 2012 (Pending);
South Africa Patent Application 2014/
04077, filed December 10, 2012
(Pending).
Licensing Contact: Dr. Vince
Contreras, 240–669–2823;
Vince.Contreras@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize Monoclonal antibodies
to treat and/or diagnose HIV and/or
AIDS.
For collaboration opportunities,
please contact Dr. Vince Contreras, 240–
669–2823; Vince.Contreras@nih.gov.
Dated: September 1, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–19088 Filed 9–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
Frm 00048
Fmt 4703
Sfmt 4703
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group Reproduction, Andrology, and
Gynecology Subcommittee.
Date: October 20, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Dennis E. Leszczynski,
Ph.D., Scientific Review Administrator
Division of Scientific Review National
Institute of Child Health and Human
Development, NIH, 6710B Bethesda Drive,
Bethesda, MD 20892, (301) 435–2717,
leszczyd@mail.nih.gov.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Point of Care
Technologies for the Evaluation and
Management of Obstetrics, Neonatal, and
Pediatric Critical Care Patients, and for
Patients With Disorders of Reproductive
Tract and Infertility.
Date: November 6, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Sathasiva B. Kandasamy,
Ph.D., Scientific Review Administrator
Division of Scientific Review National
Institute of Child Health and Human
Development, 6710B Bethesda Drive,
Bethesda, MD 20892, (301) 435–6680,
skandasa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: September 5, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–19089 Filed 9–8–17; 8:45 am]
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Closed
Meetings
PO 00000
42687
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Nursing Research
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
E:\FR\FM\11SEN1.SGM
11SEN1
]]>Agencies
[Federal Register Volume 82, Number 174 (Monday, September 11, 2017)]
[Notices]
[Page 42687]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19089]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health and
Human Development; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Child Health and Human
Development Initial Review Group Reproduction, Andrology, and
Gynecology Subcommittee.
Date: October 20, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda,
MD 20814.
Contact Person: Dennis E. Leszczynski, Ph.D., Scientific Review
Administrator Division of Scientific Review National Institute of
Child Health and Human Development, NIH, 6710B Bethesda Drive,
Bethesda, MD 20892, (301) 435-2717, leszczyd@mail.nih.gov.
Name of Committee: National Institute of Child Health and Human
Development Special Emphasis Panel; Point of Care Technologies for
the Evaluation and Management of Obstetrics, Neonatal, and Pediatric
Critical Care Patients, and for Patients With Disorders of
Reproductive Tract and Infertility.
Date: November 6, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda,
MD 20814.
Contact Person: Sathasiva B. Kandasamy, Ph.D., Scientific Review
Administrator Division of Scientific Review National Institute of
Child Health and Human Development, 6710B Bethesda Drive, Bethesda,
MD 20892, (301) 435-6680, skandasa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: September 5, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-19089 Filed 9-8-17; 8:45 am]
BILLING CODE 4140-01-P
